However, one of the major gripes about semaglutide (the active ingredient in Novo Nordisk's Ozempic and Wegovy) and ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, telehealth companies and even themselves. Since Eli Lilly's Mounjaro and ...

Any drug that can make you skinny and rich at the same time must be a miracle. Ozempic and its competitor treatments are already handling the skinny side of the equation, and they're working ...

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Eli Lilly's weight-loss drugs face rising competition from foreign upstarts, but that’s not a reason to turn bearish on the stock. Quite the opposite: analysts at Citi have significantly raised ...

Don't let soupy spuds and gray beans bring you down - there's a canned veggie out there that's even more nutritious than its ...

A new medication has the potential to be even more effective for weight loss than currently trending drugs like Ozempic and Wegovy — if patients can access it. Tirzepatide, a once-weekly ...

A game-changing medication called semaglutide, better known by the brand names Ozempic and Wegovy, has been trending for its impressive weight-loss results since 2021 — but one 47-year-old woman ...

Intense competition from Viking Therapeutics and ... landscape threaten Novo's performance moving forward. Because Ozempic was first marketed for the treatment of diabetes, these supposed 'junk ...